Publications 2024

Eng HM, Sveen KA, Fagerås SJ, Strøm MS, Diep LM, Juliusson PB, Alfsen GC (2024)
Introduction of electronic death notification in Norway-Impact on diabetes mortality registration
PLoS One, 19 (12), e0311106
DOI 10.1371/journal.pone.0311106, PubMed 39621642

Narum M, Seljeflot I, Bratseth V, Berg TJ, Sveen KA (2024)
Intestinal fatty acid binding protein is associated with coronary artery disease in long-term type 1 diabetes-the Dialong study
Cardiovasc Diabetol, 23 (1), 419
DOI 10.1186/s12933-024-02509-3, PubMed 39563343

Raknes G, Fagerås SJ, Sveen KA, Júlíusson PB, Strøm MS (2024)
Excess non-COVID-19 mortality in Norway 2020-2022
BMC Public Health, 24 (1), 244
DOI 10.1186/s12889-023-17515-5, PubMed 38254068

Ruiz PL, Karlstad Ø, Nøkleby K, Slåtsve K, Gulseth HL, Meyer HE, Sveen KA, Qvigstad E, Furu K (2024)
Pharmacological treatment of obesity in adults in Norway 2004-2022
Diabetes Obes Metab, 26 (6), 2102-2110
DOI 10.1111/dom.15515, PubMed 38419410

Sharma A, Birkeland KI, Nermoen I, Sommer C, Qvigstad E, Lee-Ødegård S, Sveen KA, Sattar N, Sollid ST, Omland T, Myhre PL (2024)
N-terminal pro-B-type natriuretic peptide levels vary by ethnicity and are associated with insulin sensitivity after gestational diabetes mellitus
Cardiovasc Diabetol, 23 (1), 284
DOI 10.1186/s12933-024-02349-1, PubMed 39097697

Publications 2023

Norhammar A, Bodegard J, Vanderheyden M, Tangri N, Karasik A, Maggioni AP, Sveen KA, Taveira-Gomes T, Botana M, Hunziker L, Thuresson M, Banerjee A, Sundström J, Bollmann A (2023)
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
Heart, 109 (7), 548-556
DOI 10.1136/heartjnl-2022-321702, PubMed 36781285

Publications 2021

Sveen KA, Bech Holte K, Svanteson M, Hanssen KF, Nilsson J, Bengtsson E, Julsrud Berg T (2021)
Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes
Diabetes Care, 44 (6), 1402-1409
DOI 10.2337/dc20-2089, PubMed 33858856

Sveen KA, Smith G, Björkbacka H, Orho-Melander M, Engström G, Gonçalves I, Melander O, Nilsson J, Bengtsson E (2021)
High levels of autoantibodies against apoB100 p210 are associated with lower incidence of atrial fibrillation in women
J Intern Med, 291 (2), 207-217
DOI 10.1111/joim.13393, PubMed 34532909

Publications 2020

Holte KB, Svanteson M, Hanssen KF, Sveen KA, Seljeflot I, Solheim S, Sell DR, Monnier VM, Berg TJ (2020)
Collagen methionine sulfoxide and glucuronidine/LW-1 are markers of coronary artery disease in long-term survivors with type 1 diabetes. The Dialong study
PLoS One, 15 (5), e0233174
DOI 10.1371/journal.pone.0233174, PubMed 32401813

Publications 2014

Sveen KA, Dahl-Jørgensen K, Stensaeth KH, Angel K, Seljeflot I, Sell DR, Monnier VM, Hanssen KF (2014)
Glucosepane and oxidative markers in skin collagen correlate with intima media thickness and arterial stiffness in long-term type 1 diabetes
J Diabetes Complications, 29 (3), 407-12
DOI 10.1016/j.jdiacomp.2014.12.011, PubMed 25600701

Sveen KA, Nerdrum T, Hanssen KF, Brekke M, Torjesen PA, Strauch CM, Sell DR, Monnier VM, Dahl-Jørgensen K, Steine K (2014)
Impaired left ventricular function and myocardial blood flow reserve in patients with long-term type 1 diabetes and no significant coronary artery disease: associations with protein glycation
Diab Vasc Dis Res, 11 (2), 84-91
DOI 10.1177/1479164113518805, PubMed 24443481

Publications 2013

Sveen KA, Karimé B, Jørum E, Mellgren SI, Fagerland MW, Monnier VM, Dahl-Jørgensen K, Hanssen KF (2013)
Small- and large-fiber neuropathy after 40 years of type 1 diabetes: associations with glycemic control and advanced protein glycation: the Oslo Study
Diabetes Care, 36 (11), 3712-7
DOI 10.2337/dc13-0788, PubMed 24026557

Publications 2012

Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljeflot I, Hanssen KF (2012)
The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial
Diabetes Care, 35 (5), 1095-7
DOI 10.2337/dc11-1895, PubMed 22446172

Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljeflot I, Hanssen KF (2012)
Response to Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Care 2012;35:1095-1097
Diabetes Care, 35 (11), E80
DOI 10.2337/dc12-1124